Synonn Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 2.77 M
- Paid Up Capital ₹ 2.77 M
- Company Age 16 Year, 2 Months
- Last Filing with ROC 31 Mar 2019
- Revenue Growth 3.61%
- Profit Growth -54.74%
- Ebitda -80.12%
- Net Worth 0.61%
- Total Assets -5.57%
About Synonn Lifesciences
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51397DL2008PLC185780
- Company No.
185780
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
12 Dec 2008
- Date of AGM
30 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
What products or services does Synonn Lifesciences Limited offer?
Synonn Lifesciences Limited offers a wide range of products and services, including Pantoprazole Drugs, Pantoprazole Sodium Injection, Antibiotic Tablets & Capsules, Linezolid Tablets, Anticoagulant and Antiplatelet Drugs, Enoxaparin Injection.
Who are the key members and board of directors at Synonn Lifesciences?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Krishnendu Dey  | Director | 12-Dec-2008 | Current |
| Rahul Patil | Director | 12-Dec-2008 | Current |
| Rajendra Goyal | Director | 02-Sep-2013 | Current |
Financial Performance of Synonn Lifesciences.
Synonn Lifesciences Limited, for the financial year ended 2016, experienced modest growth in revenue, with a 3.61% increase. The company also saw a substantial fall in profitability, with a 54.74% decrease in profit. The company's net worth moved up by a moderate rise of 0.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Synonn Lifesciences?
In 2017, Synonn Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Synonn Lifesciences?
Synonn Lifesciences has a workforce of 10 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Synonn Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Synonn Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
